Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage company headquartered in San Diego, California, has launched two novel opioids aimed at treating severe pain. Leveraging its proprietary technology platform to develop safer prescription medications, the company utilizes its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms to create a new class of opioids designed to prevent drug abuse and overdose. Ensysce’s products are expected to provide a safer option for treating severe pain and help reduce deaths caused by opioid misuse, thereby lowering human and economic costs.